Contract Development Manufacturing Organizations Market Report 2026

The contract development manufacturing organizations market size has grown rapidly in recent years. It will grow from $274.79 billion in 2025 to $309.9 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to cost optimization through outsourcing, rising r&d expenditure in pharmaceuticals, growing generic drug production, increasing regulatory complexity, limited in-house manufacturing capacity.

The contract development manufacturing organizations market size is expected to see rapid growth in the next few years. It will grow to $503.82 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to growth of biologics and advanced therapies, increasing demand for flexible manufacturing capacity, expansion of small and mid-size pharma companies, rising clinical trial activity, global pharmaceutical pipeline growth. Major trends in the forecast period include increased outsourcing of drug development and manufacturing, growing demand for integrated cdmo services, expansion of biologics and biosimilars manufacturing, rising focus on regulatory compliance and quality assurance, capacity expansion in emerging pharmaceutical markets.

The increasing demand for pharmaceutical products, driven by the rising prevalence of chronic diseases and the growing geriatric population, has contributed to the expansion of the contract development manufacturing organizations market. The growth in chronic conditions and the aging population has encouraged pharmaceutical companies to rapidly produce biologics and biosimilars, leading many firms to outsource manufacturing, testing, and operational activities to contract development and manufacturing organizations operating on a contractual basis. For example, in November 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association, reported that total pharmaceutical production in Europe reached €390.0 billion ($422,803 million) in 2023, an increase from €363.3 billion ($393,857 million) in 2022. Consequently, the rising demand for pharmaceutical products is driving the growth of the contract development manufacturing organizations market.

Leading companies operating in the contract development and manufacturing organizations market are concentrating on innovative initiatives such as Lifera to boost revenue growth. Lifera is a commercial-scale contract development and manufacturing organization (CDMO). For example, in June 2023, the Public Investment Fund (PIF), Saudi Arabia’s global investment organization, launched Lifera. Lifera’s primary focus is the production of essential biopharmaceutical products, including insulin, vaccines, monoclonal antibodies, plasma-derived therapies, cell and gene therapies, and advanced small-molecule drugs. The company also aims to increase local production capacity and support domestic manufacturing by forming partnerships with leading local and international firms and attracting targeted investments. Lifera’s objectives include advancing formulation development, drug development, and manufacturing capabilities.

In December 2023, Ajinomoto Co., Inc., a Japan-based provider of biopharmaceutical services, amino acid-based technologies, and contract development and manufacturing solutions, acquired Forge Biologics for $620 million. Through this acquisition, Ajinomoto seeks to enhance its capabilities in viral vector and plasmid gene therapy manufacturing, thereby strengthening its global contract development and manufacturing service portfolio. Forge Biologics is a US-based company specializing in adeno-associated virus and plasmid DNA manufacturing, process development, and end-to-end gene therapy CDMO services.

Major companies operating in the contract development manufacturing organizations market are Recipharm AB, AbbVie Contract Manufacturing LLC, Almac Group Limited, Baxter BioPharma Solutions LLC, Boehringer Ingelheim International GmbH, Catalent Pharma Solutions Inc., CMIC Holdings Co. Ltd., Covance Inc., Evotec SE, Famar Health Care Services Madrid SA, Jubilant Life Sciences Limited, Lonza Group Ltd., Patheon UK Limited, Pfizer CentreOne, Thermo Fisher Scientific Inc., Vetter Pharma International GmbH, Advanced BioScience Laboratories Inc., Adare Pharmaceuticals Inc., Aenova Holding GmbH, Ajinomoto Bio-Pharma Services, Albany Molecular Research Inc., Cambrex Corporation, CordenPharma International GmbH, EirGen Pharma Limited, Grand River Aseptic Manufacturing, Hovione LLC, Metrics Contract Services, NextPharma Technologies Holding Limited, Nitto Avecia Pharma Services Inc., Piramal Pharma Solutions Inc., Siegfried Holding AG, Therapure Biopharma Inc., Velesco Pharmaceutical Services, WuXi PharmaTech (Cayman) Inc.

North America was the largest region in contract development manufacturing organizations market in 2025. The regions covered in the contract development manufacturing organizations market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the contract development manufacturing organizations market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created both cost pressures and strategic shifts in the contract development manufacturing organizations market by increasing the prices of imported raw materials, APIs, specialized equipment, and laboratory consumables used in drug development and manufacturing. These impacts are most pronounced across small molecule and biologics manufacturing segments and in regions such as Asia-Pacific and Europe that are deeply integrated into global pharmaceutical supply chains. Higher tariffs have increased operating costs and extended project timelines for CDMOs serving big pharma and generic drug manufacturers. However, tariffs have also encouraged localization of manufacturing, regional capacity expansion, and long-term partnerships, strengthening domestic CDMO ecosystems in select markets.

The contract development manufacturing organizations market research report is one of a series of new reports that provides contract development manufacturing organizations market statistics, including contract development manufacturing organizations industry global market size, regional shares, competitors with a contract development manufacturing organizations market share, detailed contract development manufacturing organizations market segments, market trends and opportunities, and any further data you may need to thrive in the contract development manufacturing organizations industry. This contract development manufacturing organizations market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Contract development manufacturing organizations are companies that operate on a contractual basis with the pharmaceutical industry to deliver drug development and manufacturing services. These organizations allow pharmaceutical companies to outsource certain operations, enabling them to focus critical resources on drug development and marketing activities.

Contract development manufacturing organizations are categorized by service into CMO and CRO, by product type into small molecules and biologics, and by end user into large pharmaceutical companies, small and mid-sized pharmaceutical firms, generic pharmaceutical manufacturers, and other end users.

The contract development manufacturing organizations market includes revenues earned by entities by formulation, analytical services, blending, coating, and converting. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.